Digital Therapeutic for Schizophrenia
A new digital therapeutic, CT-155, has shown promise in reducing negative symptoms of schizophrenia.
CT-155 is a smartphone app that uses adaptive goal-setting techniques to deliver psychosocial interventions.
- Developed by Boehringer Ingelheim and Click Therapeutics
- First experimental prescription digital therapy with good tolerability and no significant adverse events
According to data presented at the 38th Annual European College of Neuropsychopharmacology Congress, CT-155 can reduce negative symptoms of schizophrenia.
An estimated 24 million people worldwide have schizophrenia, characterized by persistent delusions and hallucinations, according to the World Health Organization.
Author's summary: Digital therapeutic CT-155 reduces schizophrenia symptoms.
More News
- China, the United States, and a Critical Chokepoint on Minerals
- Fabrizio Romano has terrible news for Tottenham midfielder
- Borrower Monitoring, AI Processing, DPA, Verification Tools; Events and Training; Robots Will do What?
- How Arkansas football's No. 5 jersey patch honoring Darren McFadden came to be | Whole Hog Sports
- Manchester United’s stance on Kobbie Mainoo leaving Old Trafford in January revealed
- TBA, Appraisal, Reverse Mortgage Tools; STRATMOR on AI and Competition; Can the CFPB be Willed Away?